Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and distribution of healthcare products, including vaccines and prescription medications. Its areas of focus include immunology, oncology, cardiology, endocrinology, and infectious diseases.
Founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, the company originally produced chemicals and medical compounds. Over the years, Pfizer became one of the world’s largest pharmaceutical companies, known for developing widely used medications such as Lipitor, Viagra, and the COVID-19 vaccine, Comirnaty, developed in partnership with BioNTech.
Pfizer’s business is structured around drug development and large-scale manufacturing, with a global presence in both established and emerging markets.
Company profile
Founded: 1849
Headquarters: New York City, New York, United States
CEO: Albert Bourla
Ticker: PFE (NYSE)
Employees: ~83,000 (2024)
Investment thesis
Pfizer is a well-established pharmaceutical company with a deep research pipeline and global manufacturing scale. Its ability to bring innovative treatments to market, along with its partnerships and licensing agreements, supports steady long-term revenue.
The company gained global visibility during the COVID-19 pandemic through its mRNA vaccine and continues to invest in vaccine technology, oncology, and rare disease treatments. It also generates stable revenue from established medications and recently acquired Seagen to expand its oncology portfolio.
Pfizer’s scale, brand trust, and research capabilities help position it to respond to public health needs and evolving disease trends.
Investment considerations
Risk factors: Loss of exclusivity on key drugs, regulatory hurdles, R&D setbacks, pricing pressure, and shifting post-pandemic demand. Pfizer also faces legal risks, including lawsuits alleging COVID-19 vaccine misrepresentation and a $59.7 million settlement in 2025 over migraine drug kickbacks. Past fines for unlawful marketing and ongoing scrutiny around rare vaccine side effects, like myocarditis, may affect public perception and future product uptake.
Growth opportunities: Development of new vaccines and therapeutics, expansion in oncology and rare diseases, and entry into new global markets.
Market dynamics: As a major pharmaceutical firm, Pfizer plays a central role in global healthcare. While pandemic-related revenue has declined, its broader portfolio and ongoing innovation support its long-term positioning in the sector.
